SELLAS Life Sciences Group reports positive results from mid-stage lymphoma treatment trial
SELLAS Life Sciences Group (NASDAQ:SLS) announced on Thursday promising mid-stage trial results for SLS009, a highly ...
Bantam Pharmaceutical Announces Activation of First Phase 1 Clinical Trial Site at MD Anderson Cancer Center
Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in ...
SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL
Combination Achieved a 67% of Overall Response Rate, More than Double that of Zanubrutinib Alone; 83% Disease Control Rate in ...
manilatimes7h
Greenheart Gold Has Entered Into an Option Agreement to Acquire a 100% Interest in the Tosso Creek Exploration Project in Suriname
The 96-square-kilometer Tosso Creek Project is located in southern Suriname, approximately 180 km south of the capital city, ...
Sellas Life Sciences’ zanubrutinib combination shows efficacy in DLBCL
Sellas Life Sciences (SLS) announced data from Phase 2a trial of SLS009 – tambiciclib -, a highly selective CDK9 inhibitor, in ...
SELLAS Life Sciences Group, Inc.: SELLAS Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL
Combination Achieved a 67% of Overall Response Rate, More than Double that of Zanubrutinib Alone; 83% Disease Control Rate in Difficult-to-Treat Non-GCB DLBCL (ABC DLBCL) Patients - - Median Overall ...